Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611073 · ClinicalTrials.gov registry record
Maximizing Visual Outcomes With Eyhance IOLs
A clinical trial, sponsored by Berkeley Eye Center.
- Completed
- Registry status
- 110
- Enrollment target
NCT05611073: Completed study, sponsored by Berkeley Eye Center.
NCT05611073 is a clinical trial that has completed, run by Berkeley Eye Center. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611073 has completed, sponsored by Berkeley Eye Center.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
This is a non-interventional prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had bilateral implantation of an Eyhance IOL at the time of cataract surgery. These patients will then be compared to assess which patient biometric properties (such as spherical aberration, q value, pupil size, etc.) lead to an overall increase in near or intermediate vision as well as overall patient satisfaction.
Primary Outcome
To compare two groups categorized by "distance with minimal intermediate" and "distance with enhanced intermediate/near" based on mean photopic binocular BCDVA of patients with bilateral Eyhance IOLs targeted corrected at plano sphere.
Interventions
- DIAGNOSTIC_TEST Visual Acuity
- DIAGNOSTIC_TEST Biometric Data Collection
- OTHER Patient Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2022-11-07 |
What the finished NCT05611073 record still lists
NCT05611073 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Visual Acuity is the first listed.
NCT05611073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05611073 about?
NCT05611073 is a clinical study titled "Maximizing Visual Outcomes With Eyhance IOLs". This is a non-interventional prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had bilateral implantation of an Eyhance IOL at the time of cataract surgery. These patients will then be compared to assess which patient biometric pr...
What is the current status of trial NCT05611073?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2022-03-07. Estimated completion is 2022-11-07.
What interventions are being tested in trial NCT05611073?
The interventions under investigation include: Visual Acuity (DIAGNOSTIC_TEST), Biometric Data Collection (DIAGNOSTIC_TEST), Patient Questionnaire (OTHER).
Who is sponsoring clinical trial NCT05611073?
This trial is sponsored by Berkeley Eye Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI